| # | Country | Total Patents | |
|---|---|---|---|
| #1 | United States | 3 | |
| #2 | Australia | 2 | |
| #3 | Canada | 2 | |
| #4 | EPO (European Patent Office) | 2 | |
| #5 | WIPO (World Intellectual Property Organization) | 2 |
| # | Industry | |
|---|---|---|
| #1 | Pharmaceuticals |
| # | Technology | |
|---|---|---|
| #1 | Medical preparations | |
| #2 | Therapeutic chemical compounds |
| # | Name | Total Patents |
|---|---|---|
| #1 | Scheibler Lukas | 11 |
| #2 | Schiffman Rhett M | 10 |
| #3 | Schiffman Rhett | 1 |
| Publication | Filing date | Title |
|---|---|---|
| US2021121534A1 | Sustained-release drug delivery systems comprising an intraocular pressure lowering agent, a cnp compound, an npr-b compound, a tie-2 agonist, or neurotrophic agent for use for treating glaucoma or ocular hypertension | |
| AU2019290582A1 | Drug delivery systems comprising a neurotrophic agent, an apoptosis signaling fragment inhibitor (FAS) or FAS ligand (FASL) inhibitor, a tumor necrosis factor-alpha (TNF-alpha) or TNF receptor inhibitor, a mitochondrial peptide, an oligonucleotide, a chemokine inhibitor, or a cysteine-aspartic protease |